Lower maintenance?

Swiss pharmaceutical manufacturer Roche is claiming its new experimental once-a-week oral medication for type-2 diabetes works better than Merck’s hotly-hyped daily Januvia.

The stuff is known as taspoglutide — no cute brand name yet — and it has a certain appeal to those of us who pop six tablets a day.

On t’other hand, those ancient remedies I take run around $20 a month; it’s a safe bet Roche will be asking a lot more than that for their new pill. And inasmuch as my glucose levels aren’t off the scale, I probably don’t need the higher tech. (Last reading: 128 mg/dl, which isn’t praiseworthy, but which isn’t going to cause a Death Panel to be convened on my, um, behalf.)





Comments are closed.